400 related articles for article (PubMed ID: 15557508)
21. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease.
Wolk DA; Dickerson BC;
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10256-61. PubMed ID: 20479234
[TBL] [Abstract][Full Text] [Related]
22. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
23. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
Fleisher AS; Sun S; Taylor C; Ward CP; Gamst AC; Petersen RC; Jack CR; Aisen PS; Thal LJ
Neurology; 2008 Jan; 70(3):191-9. PubMed ID: 18195264
[TBL] [Abstract][Full Text] [Related]
24. Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study.
Liu Y; Paajanen T; Westman E; Wahlund LO; Simmons A; Tunnard C; Sobow T; Proitsi P; Powell J; Mecocci P; Tsolaki M; Vellas B; Muehlboeck S; Evans A; Spenger C; Lovestone S; Soininen H;
J Alzheimers Dis; 2010; 21(3):947-66. PubMed ID: 20693633
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan.
Wang PN; Lirng JF; Lin KN; Chang FC; Liu HC
Neurobiol Aging; 2006 Dec; 27(12):1797-806. PubMed ID: 16321457
[TBL] [Abstract][Full Text] [Related]
26. Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly.
Dik MG; Jonker C; Comijs HC; Bouter LM; Twisk JW; van Kamp GJ; Deeg DJ
Neurology; 2001 Dec; 57(12):2217-22. PubMed ID: 11756600
[TBL] [Abstract][Full Text] [Related]
27. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
Kennedy RE; Cutter GR; Schneider LS
Alzheimers Dement; 2014 May; 10(3):349-59. PubMed ID: 23712001
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
29. The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology.
Ramakers IH; Visser PJ; Aalten P; Bekers O; Sleegers K; van Broeckhoven CL; Jolles J; Verhey FR
Dement Geriatr Cogn Disord; 2008; 26(2):101-8. PubMed ID: 18617739
[TBL] [Abstract][Full Text] [Related]
30. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
Löwe LC; Gaser C; Franke K;
PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
[TBL] [Abstract][Full Text] [Related]
31. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
[TBL] [Abstract][Full Text] [Related]
32. APOE-ε4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies.
Saeed U; Mirza SS; MacIntosh BJ; Herrmann N; Keith J; Ramirez J; Nestor SM; Yu Q; Knight J; Swardfager W; Potkin SG; Rogaeva E; St George-Hyslop P; Black SE; Masellis M
Alzheimers Dement; 2018 Sep; 14(9):1137-1147. PubMed ID: 29782824
[TBL] [Abstract][Full Text] [Related]
33. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
34. Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease.
Morgen K; Ramirez A; Frölich L; Tost H; Plichta MM; Kölsch H; Rakebrandt F; Rienhoff O; Jessen F; Peters O; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Hampel H; Teipel SJ; Pantel J; Heuser I; Wiltfang J; Rüther E; Kornhuber J; Maier W; Meyer-Lindenberg A
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S269-76. PubMed ID: 24613704
[TBL] [Abstract][Full Text] [Related]
35. Cognitive deficits and polymorphism of apolipoprotein E in Alzheimer's disease.
Luczywek E; Nowicka A; Pfeffer A; Czyzewski K; Styczyńska M; Lałowski M; Barcikowska M
Dement Geriatr Cogn Disord; 2002; 13(3):171-7. PubMed ID: 11893839
[TBL] [Abstract][Full Text] [Related]
36. Predicting the apolipoprotein E ε4 allele carrier status based on gray matter volumes and cognitive function.
Kim HG; Tian Y; Jung SM; Park S; Rhee HY; Ryu CW; Jahng GH
Brain Behav; 2024 Jan; 14(1):e3381. PubMed ID: 38376028
[TBL] [Abstract][Full Text] [Related]
37. APOE polymorphisms and cognitive functions in patients with brain tumors.
Correa DD; Satagopan J; Baser RE; Cheung K; Richards E; Lin M; Karimi S; Lyo J; DeAngelis LM; Orlow I
Neurology; 2014 Jul; 83(4):320-7. PubMed ID: 24944262
[TBL] [Abstract][Full Text] [Related]
38.
Mirza SS; Saeed U; Knight J; Ramirez J; Stuss DT; Keith J; Nestor SM; Yu D; Swardfager W; Rogaeva E; St George Hyslop P; Black SE; Masellis M;
Neurology; 2019 Nov; 93(19):e1807-e1819. PubMed ID: 31575706
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.
Elias-Sonnenschein LS; Viechtbauer W; Ramakers IH; Verhey FR; Visser PJ
J Neurol Neurosurg Psychiatry; 2011 Oct; 82(10):1149-56. PubMed ID: 21493755
[TBL] [Abstract][Full Text] [Related]
40. The joint effect of apolipoprotein E epsilon4 and MRI findings on lower-extremity function and decline in cognitive function.
Carmelli D; DeCarli C; Swan GE; Kelly-Hayes M; Wolf PA; Reed T; Guralnik JM
J Gerontol A Biol Sci Med Sci; 2000 Feb; 55(2):M103-9. PubMed ID: 10737693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]